PIK3R3
ENSG00000117461
Target class
Kinase
Chromosome
1
Approved drugs
0
Clinical candidates (approved and in development)
26
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 26
- Chemical probe available
- No
- Other names
- p55
- Target name
- PIK3R3
- Gene name
- Phosphoinositide-3-kinase regulatory subunit 3
- Gene symbol
- PIK3R3
- Protein name
- Phosphatidylinositol 3-kinase regulatory subunit gamma (PI3-kinase regulatory subunit gamma) (PI3K regulatory subunit gamma) (PtdIns-3-kinase regulatory subunit gamma) (Phosphatidylinositol 3-kinase 55 kDa regulatory subunit gamma) (PI3-kinase subunit p55-gamma) (PtdIns-3-kinase regulatory subunit p55-gamma) (p55PIK)
- Gene biotype
- Protein coding
- Gene family
- SH2 domain containing
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 69.52
- Tissue specificity (Gini)
- 0.423
- Tissue specificity (tau)
- 0.806
- KEGG gene identifiers
- hsa:8503
- Protein interaction confidence
- 0.900268
- Protein interaction partners
- 138
- R-HSA-114604
- R-HSA-1257604
- R-HSA-1266695
- R-HSA-1433557
- R-HSA-1660499
- R-HSA-2219530
- R-HSA-389357
- R-HSA-416476
- R-HSA-512988
- R-HSA-6811558
- R-HSA-8853659
- R-HSA-9009391
- R-HSA-9013149
- R-HSA-9013404
- R-HSA-912526
- R-HSA-912631
- R-HSA-9670439
- R-HSA-9927354
- End position
- 46133338
- Start position
- 46040140
- Chromosome
- 1
- Strand
- Reverse
- Connecting piece
- Cytosol
- End piece
- Mid piece
- Nucleoplasm
- Principal piece
- Tissue specificity (tau)
- 0.805784
- Expression inequality (Gini)
- 0.423038
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 69.52
- Brain - Cerebellum
- 62.8
- Testis
- 43.06
- Adipose - Subcutaneous
- 37.98
- Adipose - Visceral (Omentum)
- 33.64
Expression in transcripts per million
- Brain - Cerebellar Hemisphere69.52
- Brain - Cerebellum62.8
- Testis43.06
- Adipose - Subcutaneous37.98
- Adipose - Visceral (Omentum)33.64
- Breast - Mammary Tissue32.95
- Lung25.08
- Uterus23.48
- Thyroid23.39
- Nerve - Tibial19.6
- Fallopian Tube17.09
- Bladder17
- Prostate16.71
- Esophagus - Gastroesophageal Junction16.34
- Minor Salivary Gland15.53
- Kidney - Medulla15.47
- Cervix - Endocervix15.27
- Esophagus - Muscularis14.39
- Cells - EBV-transformed lymphocytes13.22
- Spleen13.21
- Heart - Left Ventricle13.03
- Artery - Coronary12.48
- Heart - Atrial Appendage12.37
- Pituitary11.97
- Adrenal Gland11.93
And 29 more, listed on the interactive page.
- GO:0002042
- GO:0008286
- GO:0010628
- GO:0043491
Cellular components
- GO:0005829
- GO:0001784
- GO:0005515
- GO:0016303
Related records
Trials (197)
- 5G-PEARL: Paxalisib in Malignant Brain Tumours
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
- A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
- A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
- A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
- A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
- A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
- A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
- A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
- A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
- A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
- A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
- A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
Drugs (28)
- Apitolisib PI3-kinase class I inhibitor
- AZD-6482 PI3-kinase class I inhibitor
- BGT-226 PI3-kinase class I inhibitor
- BGT-226 FREE BASE PI3-kinase class I inhibitor
- Buparlisib PI3-kinase class I inhibitor
- Dactolisib PI3-kinase class I inhibitor
- DS-7423 PI3-kinase class I inhibitor
- Gedatolisib PI3-kinase class I inhibitor
- GSK-1059615 PI3-kinase class I inhibitor
- Izorlisib PI3-kinase class I inhibitor
- Omipalisib PI3-kinase class I inhibitor
- Panulisib PI3-kinase class I inhibitor
- Paxalisib PI3-kinase class I inhibitor
- PF-04691502 PI3-kinase class I inhibitor
- Pictilisib PI3-kinase class I inhibitor
- Pilaralisib PI3-kinase class I inhibitor
- Puquitinib PI3-kinase class I inhibitor
- Puquitinib mesylate dihydrate PI3-kinase class I inhibitor
- PWT-33587 PI3-kinase class I inhibitor
- Recilisib PI3-kinase class I inhibitor